Title: Changing paradigms in management of metastatic Castration Resistant Prostate Cancer (mCRPC).
Journal: BMC urology 20140101
Title: The evolving paradigm of second-line hormonal therapy options for castration-resistant prostate cancer.
Journal: Current opinion in oncology 20120501
Title: Direct regulation of androgen receptor activity by potent CYP17 inhibitors in prostate cancer cells.
Journal: The Journal of biological chemistry 20120203
Title: Structures of cytochrome P450 17A1 with prostate cancer drugs abiraterone and TOK-001.
Journal: Nature 20120202
Title: Synthesis and biological evaluations of putative metabolically stable analogs of VN/124-1 (TOK-001): head to head anti-tumor efficacy evaluation of VN/124-1 (TOK-001) and abiraterone in LAPC-4 human prostate cancer xenograft model.
Journal: Steroids 20111101
Title: CYP17 inhibitors for prostate cancer therapy.
Journal: The Journal of steroid biochemistry and molecular biology 20110501
Title: Prolonging hormone sensitivity in prostate cancer xenografts through dual inhibition of AR and mTOR.
Journal: British journal of cancer 20100928
Title: CYP17 inhibition as a hormonal strategy for prostate cancer.
Journal: Nature clinical practice. Urology 20081101
Title: 17alpha-Hydroxylase/17,20 lyase inhibitor VN/124-1 inhibits growth of androgen-independent prostate cancer cells via induction of the endoplasmic reticulum stress response.
Journal: Molecular cancer therapeutics 20080901
Title: Androgen receptor inactivation contributes to antitumor efficacy of 17{alpha}-hydroxylase/17,20-lyase inhibitor 3beta-hydroxy-17-(1H-benzimidazole-1-yl)androsta-5,16-diene in prostate cancer.
Journal: Molecular cancer therapeutics 20080801
Title: Synergistic effect of a novel antiandrogen, VN/124-1, and signal transduction inhibitors in prostate cancer progression to hormone independence in vitro.
Journal: Molecular cancer therapeutics 20080101
Title: Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model.
Journal: Journal of medicinal chemistry 20050421
Title: Bruno RD, et al. Synthesis and biological evaluations of putative metabolically stable analogs of VN/124-1 (TOK-001): head to head anti-tumor efficacy evaluation of VN/124-1 (TOK-001) and abiraterone in LAPC-4 human prostate cancer xenograft model.Steroid
Title: DeVore NM, et al. Structures of cytochrome P450 17A1 with prostate cancer drugs abiraterone and TOK-001.Nature. 2012 Jan 22;482(7383):116-9.
Title: Soifer HS, et al. Direct regulation of androgen receptor activity by potent CYP17 inhibitors in prostate cancer cells.J Biol Chem. 2012 Feb 3;287(6):3777-87. Epub 2011 Dec 15.
